Page 52 - Read Online

Matrone et al. J Cancer Metastasis Treat 2021;7:23 https://dx.doi.org/10.20517/2394-4722.2021.47 Page 19 of 19

122. Schott M, Feldkamp J, Klucken M, Kobbe G, Scherbaum WA, Seissler J. Calcitonin-specific antitumor immunity in medullary
thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 2002;51:663-8. DOI PubMed
123. Bachleitner-Hofmann T, Friedl J, Hassler M, et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic
tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep 2009;21:1585-92. DOI PubMed
124. Bongiovanni M, Rebecchini C, Saglietti C, et al. Very low expression of PD-L1 in medullary thyroid carcinoma. Endocr Relat
Cancer 2017;24:L35-8. DOI PubMed PMC
125. Bi Y, Ren X, Bai X, et al. PD-1/PD-L1 expressions in medullary thyroid carcinoma: clinicopathologic and prognostic analysis of
Chinese population. Eur J Surg Oncol 2019;45:353-8. DOI PubMed
126. Pozdeyev N, Erickson TA, Zhang L, et al. Comprehensive immune profiling of medullary thyroid cancer. Thyroid 2020;30:1263-79.
DOI PubMed PMC
127. Shi X, Li CW, Tan LC, et al. Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid
cancers: a large cohort study. J Clin Endocrinol Metab 2021;106:120-32. DOI PubMed
128. Shi X, Yu PC, Lei BW, et al. Association between programmed death-ligand 1 expression and clinicopathological characteristics,
structural recurrence, and biochemical recurrence/persistent disease in medullary thyroid carcinoma. Thyroid 2019;29:1269-78. DOI
PubMed
129. Castellone MD, Melillo RM. RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine
neoplasia type 2 (MEN2). Endocr Relat Cancer 2018;25:T105-19. DOI PubMed
130. Faggiano A, Grimaldi F, Pezzullo L, et al. Secretive and proliferative tumor profile helps to select the best imaging technique to
identify postoperative persistent or relapsing medullary thyroid cancer. Endocr Relat Cancer 2009;16:225-31. DOI PubMed
131. De Luca S, Fonti R, Camera L, et al. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with
metastatic medullary thyroid carcinoma. Ann Nucl Med 2016;30:234-41. DOI PubMed
132. Mato E, Matías-Guiu X, Chico A, et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid
carcinoma. J Clin Endocrinol Metab 1998;83:2417-20. DOI PubMed
133. Baudin E, Lumbroso J, Schlumberger M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid
carcinoma. J Nucl Med 1996;37:912-6. PubMed
68
134. Yamaga LYI, Cunha ML, Campos Neto GC, et al. Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-
111
lesion comparison with In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging 2017;44:1695-701. DOI
PubMed
135. Bodei L, Handkiewicz-Junak D, Grana C, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary
thyroid carcinomas. Cancer Biother Radiopharm 2004;19:65-71. DOI PubMed
136. Satapathy S, Mittal BR, Sood A, Verma R, Panda N. Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose
capecitabine in advanced medullary thyroid carcinoma: a single-centre experience. Nucl Med Commun 2020;41:629-35. DOI
PubMed
137. Parghane RV, Naik C, Talole S, et al. Clinical utility of 177 Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic
medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. Head Neck
2020;42:401-16. DOI PubMed
138. DeGroot LJ. Management of thyroid nodules: how far have we come? Hosp Pract (Off Ed) 1986;21:9-10. PubMed
139. Lapa C, Werner RA, Schmid JS, et al. Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients
with thyroid cancer undergoing treatment with radiopeptide therapy. Nucl Med Biol 2015;42:349-54. DOI PubMed
140. Vaisman F, Rosado de Castro PH, Lopes FP, et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid
cancer? Clin Nucl Med 2015;40:123-7. DOI PubMed
141. Gao Z, Biersack HJ, Ezziddin S, Logvinski T, An R. The role of combined imaging in metastatic medullary thyroid carcinoma:
111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol 2004;130:649-56.
DOI PubMed
142. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid
infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207-16. DOI PubMed
143. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl
Med 2001;28:426-34. DOI PubMed
144. Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic
progressive neuroendocrine neoplasms. Surgery 2004;136:1218-26. DOI PubMed
145. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated
neuroendocrine tumors. J Nucl Med 2003;44:1-6. PubMed
146. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the
Rotterdam experience. Semin Nucl Med 2002;32:110-22. DOI PubMed
147. Iten F, Müller B, Schindler C, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in
metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 2007;13:6696-702. DOI PubMed
148. Beukhof CM, Brabander T, van Nederveen FH, et al. Peptide receptor radionuclide therapy in patients with medullary thyroid
carcinoma: predictors and pitfalls. BMC Cancer 2019;19:325. DOI PubMed PMC
149. Behr TM, Béhé MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and
other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32:97-109. DOI PubMed